發(fā)布時間：2019-07-16 18:01

【摘要】：目的:觀察凍干重組人腦利鈉肽治療急性左心功能衰竭的臨床療效及安全性。方法:將60例急性左心功能衰竭患者,按隨機數(shù)字表法分為觀察組和對照組,各30例。對照組患者給予吸氧、利尿、強心、擴張血管、控制心律失常及抑制心室重構(gòu)等常規(guī)治療;觀察組患者在對照組基礎(chǔ)上加用凍干重組人腦利鈉肽注射液1.5μg/kg靜脈推注,然后以0.007 5μg/(kg·min),ivgtt,72 h。觀察兩組患者臨床療效及治療前后左心室舒張末期內(nèi)徑(LVDD)、左心室射血分數(shù)(LVEF)、腎上腺素(E)、去甲腎上腺素(NE)、腎素活性(PRA)、血管緊張素Ⅱ(AngⅡ)、醛固酮(ALD)水平,并記錄其不良反應(yīng)。結(jié)果:觀察組患者總有效率明顯高于對照組(83.33%vs.60.00%),差異有統(tǒng)計學(xué)意義(P0.05)。治療前,兩組患者LVDD、LVEF、E、NE、PRA、AngⅡ、ALD水平比較,差異無統(tǒng)計學(xué)意義(P0.05);治療后,兩組患者上述指標均顯著改善,且觀察組改善程度顯著優(yōu)于對照組,差異均有統(tǒng)計學(xué)意義(P0.05);兩組患者均未見明顯不良反應(yīng)發(fā)生。結(jié)論:凍干重組人腦利鈉肽治療急性左心功能衰竭療效顯著,且安全性較好。
[Abstract]:Objective: to observe the clinical efficacy and safety of freeze-dried recombinant human brain natriuretic peptide in the treatment of acute left ventricular failure. Methods: sixty patients with acute left ventricular failure were randomly divided into observation group (n = 30) and control group (n = 30). The patients in the control group were given routine treatment such as oxygen inhalation, diuresis, cardiotonic strength, vasodilation, control of arrhythmia and inhibition of ventricular remodeling, while the patients in the observation group were injected intravenously with lyophilized recombinant human brain natriuretic peptide injection 1.5 渭 g / kg and then 0.007 5 渭 g / (kg 路min), ivgtt,72 h). The clinical efficacy and left ventricular end-diastolic diameter (LVDD), left ventricular ejection fraction (LVEF), adrenalin (E), norepinephrine (NE), renin activity (PRA), angiotensin 鈪，

本文編號：2515183